Navigation Links
Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
Date:3/28/2009

Hughes, MA, DPhil, MRCPath, Senior Lecturer in the Haematology Department Academic Haematology, Royal Free & University College Medical School, London, UK, stated, "The data with migalastat continue to be encouraging. I believe migalastat has the potential to be an important new treatment option for Fabry patients."

John F. Crowley, President and CEO of Amicus Therapeutics, added, "We are very pleased with this additional set of Phase 2 data and are very confident we have a solid basis for a successful Phase 3 program. We continue to work in collaboration with the FDA and remain on track to finalize our protocol and initiate the Phase 3 program in the second quarter of this year."

In January 2009, Amicus announced that the FDA supports a Phase 3 clinical trial comparing Amigal to placebo based on a surrogate primary endpoint of the change in the amount of kidney GL-3, the substrate that accumulates in the cells of Fabry patients. The Company expects to finalize the protocol and initiate Phase 3 development in the second quarter of this year.

Amicus is developing Amigal as part of a strategic collaboration with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the agreement, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

About Fabry Disease

Fabry disease is a lysosomal storage disorder caused by inherited genetic mutations in the GLA gene, which result in deficient activity of the enzyme alpha-galactosidase A (a-Gal A). Deficient a-Gal A activity leads to lysosomal accumulation of globotriaosylceramide (GL-3), which is believed to cause the various symptoms of Fabry disease, including pain, kidney failure and increased risk of heart attack and stroke. Amigal is designed to selectively bind to
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
2. Amicus Therapeutics Announces Change to Board of Directors
3. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
4. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
5. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
8. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
9. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
10. Amicus Therapeutics Opens Research Facility in San Diego
11. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Village, Calif. (PRWEB) January 15, 2014 ... treatment and management through the genomic analysis of tumor ... offer Therapy Finder™, a web-based cancer decision support application ... reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder ...
(Date:1/15/2014)... A study has been launched to test whether technology ... help to tackle the problem of obesity.  This unique healthcare ... based in Stowmarket) and academics at University Campus Suffolk is ... which is inspired by equipment used to collect data about ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS Language ... its Online Web Portal for Life Science organizations who need ... specify the subject matter of their documents in advance with ... help reduce time-to-delivery of translations, often a critical factor in ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... -- The president of Cars.com and one ... and other Internet topics in the Sept. 29 inaugural speaker ... , ,The speaker, Mitch Golub, has an extensive background in ... joined Classified Ventures, which includes Cars.com, after a 21-year career ...
... Madison, Wis. - An improved warning system could ... representatives of a Madison company involved in emergency communications. ... the levees were breached, where people could have been ... said Kendall Post, chief technology officer of Madison-based ...
... Inc., has launched interactive, personalized services for Milwaukee ... the company announced Thursday. Traffic.com will provide area ... displays of roadway traffic conditions including congestion levels, ... in a news release. , ,Data for the ...
Cached Biology Technology:Cars.com president slated for Milwaukee event 2Madison company urges disaster warning upgrades 2
(Date:4/23/2014)... signing ceremony in Buenos Aires yesterday, Argentina joins ... associate member state. The move strengthens the ties ... communities. It grants Argentinian scientists access to EMBL,s ... collaborations. , "Ever since its inception, fostering excellent ... been at the core of EMBL,s mission," says ...
(Date:4/23/2014)... of the family of bacteria that causes whooping ... reveals surprising findings about the bacteria,s origin and ... strategies to control this respiratory disease, which kills ... of 343 strains of the Bordetella pertussis ... the last 100 years illustrates how vaccination has ...
(Date:4/23/2014)... social mammals, ravens form different types of social relationships ... they also form strict dominance relations. From a cognitive ... key ability in daily social life ("knowing who is ... members have with each other sets the stage for ... of this study have been published in the scientific ...
Breaking Biology News(10 mins):Impact of whooping cough vaccination revealed 2Ravens understand the relations among others 2
... (OTC,Bulletin Board: CICI) -- Communication Intelligence Corporation ("CIC" ... solutions for,the financial industry and the recognized leader ... for the fourth quarter,and the year ended December ... ended December 31, 2007 increased 63% to,$800,000, compared ...
... article entitled Passage Times for Polymer Translocation Pulled ... 5, of the Biophysical Journal, which is available online. ... Pulled through a Narrow Pore When polymeric ... a process known as translocation, they leave a distinct ...
... The growth in China,s carbon dioxide (CO2) emissions is ... atmospheric greenhouse gases even more difficult, according to a ... Berkeley, and UC San Diego. Previous estimates, including ... say the region that includes China will see a ...
Cached Biology News:Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2007 Results 2Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2007 Results 3Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2007 Results 4Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2007 Results 5Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2007 Results 6Media highlights for February in Biophysical Journal 2Alarming growth in expected CO2 emissions in China, finds UC analysis 2Alarming growth in expected CO2 emissions in China, finds UC analysis 3
...
... with the xPONENT Software Interface is ... assays using Upstate's Beadlyte® reagents. This ... friendly xPONENT software developed by Luminex. ... for commercial or home-made multiplex kits. ...
... turntable. Provides up to 30 minutes of walkaway time. Automatic Calibration. Five minute ... RS-232 port. ... ... ...
Vybrant® Multidrug Resistance Assay Kit...
Biology Products: